Tag: EHRA 2024
Early results of dual energy catheter system reported at EHRA 2024
Three-month follow-up results from the SmartfIRE clinical trial, investigating Biosense Webster’s Thermocool Smarttouch SF dual energy catheter were presented in a late-breaking trial session...
EHRA 2024: Closed loop stimulation rate-adaptive pacing may delay sub-clinical AF...
Clinical findings of the B3 study, assessing the impact of closed loop stimulation on the incidence of sub-clinical atrial fibrillation (AF) in sinus node...
EHRA 2024: Sphere-360 study reports first-in-man results of Medtronic PFA catheter
Interim first-in-human clinical safety and efficacy results for Medtronic’s Sphere-360 investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of...
EHRA 2024: Preventive ablation may hold promise for ventricular tachycardia
A randomised trial investigating preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of...
EHRA 2024: Cryocure-VT trial results “promising” for VT ablation
A trial of technology using ultra-low temperature cryoablation (ULTC) has shown that the technique eliminated clinical ventricular tachycardia (VT) in 94% of patients.
The finding...
EHRA 2024: Societies update consensus statement on catheter or surgical ablation
An international consensus statement on how to treat atrial fibrillation (AF) with catheter or surgical ablation has been published today in EP Europace and...